DPP-4 Inhibitors in Mealtime Insulin Management

Mechanism of Action and Benefits

• DPP-4 inhibitors work by increasing the endogenous levels of GLP-1 by reducing its deactivation, enhancing insulin secretion and inhibiting glucagon secretion in a glucose-dependent manner, with moderate glucose-lowering efficacy, reducing HbA1c by approximately 0.4% to 0.9% 1, 2
• DPP-4 inhibitors specifically target postprandial glucose control by reducing postprandial glucagon secretion and working in a glucose-dependent manner, which minimizes hypoglycemia risk 1

Safety Considerations

• DPP-4 inhibitors have minimal risk of hypoglycemia when used as monotherapy, but caution is needed when combined with insulin, and most DPP-4 inhibitors require dose adjustment in renal impairment, with linagliptin being the exception 1, 2
• Some DPP-4 inhibitors (saxagliptin and alogliptin) have been associated with increased risk of heart failure hospitalization, requiring caution in patients with cardiac disease 1, 3

Common Pitfalls and Caveats

• DPP-4 inhibitors have less potent glucose-lowering effects compared to GLP-1 receptor agonists, and rare but increased rates of pancreatitis and musculoskeletal side effects have been reported with DPP-4 inhibitors 1

DPP-4 Inhibitors for Type 2 Diabetes

Introduction to DPP-4 Inhibitors

• The American Diabetes Association recommends the use of DPP-4 inhibitors, including sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin, for the treatment of type 2 diabetes 4, 5

Clinical Use

• DPP-4 inhibitors can be used as monotherapy or in combination with other antidiabetic medications, such as metformin, thiazolidinediones, sulfonylureas, or insulin, with minimal risk of hypoglycemia when used as monotherapy 6, 4, 5
• The addition of DPP-4 inhibitors to sulfonylurea therapy increases the risk for hypoglycemia by approximately 50% compared to sulfonylurea therapy alone 4, 5

Safety Considerations

• Linagliptin has minimal renal excretion and does not require dose adjustment in renal impairment, unlike most other DPP-4 inhibitors 4, 5
• Cardiovascular safety trials have demonstrated cardiovascular safety but no cardiovascular benefit for sitagliptin, saxagliptin, and alogliptin 4, 5
• Saxagliptin and alogliptin have been associated with imbalances regarding heart failure risk 4, 5, 6

Pharmacokinetic Differences

• DPP-4 inhibitors are generally weight-neutral, unlike some other diabetes medications 4, 5

Comparing DPP-4 Inhibitors for Type 2 Diabetes Management

Efficacy and Safety Considerations

• DPP-4 inhibitors, including linagliptin and sitagliptin, have similar efficacy profiles according to the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) consensus reports 7, 8

Clinical Advantages and Safety

• Linagliptin requires no dose adjustment in patients with any degree of renal impairment, making it valuable for patients with chronic kidney disease 9
• Linagliptin plus sliding-scale insulin showed similar glycemic control to basal-bolus insulin regimens with significantly reduced hypoglycemia risk in surgical patients with type 2 diabetes and mild-to-moderate hyperglycemia 10
• Both linagliptin and sitagliptin have similar safety profiles with low risk of hypoglycemia when used as monotherapy, and are generally weight-neutral 9
• Neither medication has demonstrated cardiovascular benefit, unlike some GLP-1 receptor agonists and SGLT2 inhibitors 11

Clinical Decision Making and Recommendations

• For patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors or GLP-1 receptor agonists would be preferred over either DPP-4 inhibitor 11
• The American Diabetes Association recommends considering the cardiovascular profile of antihyperglycemic agents, including DPP-4 inhibitors like linagliptin and sitagliptin, in clinical decision making 7, 8

DPP-4 Inhibitors for Blood Sugar Reduction

Efficacy and Clinical Considerations

• DPP-4 inhibitors are less effective in patients with higher baseline HbA1c values, with treatment failure independently associated with higher HbA1c values 12
• The addition of DPP-4 inhibitors to other therapies may have specific considerations, such as increased risk of hypoglycemia, and should be used with caution in patients with certain conditions, such as cardiac disease 12

Hospital Use and Safety

• DPP-4 inhibitors are not recommended for routine use in hospital settings, though they have shown effectiveness in combination with basal insulin for hospitalized patients with mild-to-moderate hyperglycemia 12
• Professional societies recommend against the use of sulfonylureas in the hospital because of the potential risk of sustained hypoglycemia, making DPP-4 inhibitors a potentially safer option in this setting 12

Linagliptin as a Safe Alternative for Patients with Sitagliptin Allergy

Introduction to Linagliptin

• Linagliptin is a safe alternative for patients allergic to sitagliptin, as it has a different molecular structure while belonging to the same DPP-4 inhibitor class, and does not require dose adjustment in renal impairment 13

DPP-4 Inhibitors in Type 2 Diabetes Management

Clinical Positioning and Cardiovascular Safety

• The American Diabetes Association recommends DPP-4 inhibitors as second-line therapy for patients with type 2 diabetes with BMI <30 kg/m², but should be avoided in patients with heart failure risk, particularly saxagliptin which has been associated with increased heart failure hospitalization 14, 15
• For patients with BMI <30 kg/m², DPP-4 inhibitors and SGLT2 inhibitors are considered equally preferable second-line treatment options after metformin 14
• Saxagliptin is not recommended in patients with type 2 diabetes and a high risk of heart failure 16, 17
• In the SAVOR TIMI-53 trial, saxagliptin was associated with a 27% relative increase in the risk of heart failure hospitalization 15, 18
• Sitagliptin and linagliptin have shown a neutral effect on risk of heart failure and may be considered in patients without significant cardiac disease 16, 17
• The TECOS trial demonstrated no impact of sitagliptin on risk of cardiovascular events or heart failure hospitalization 15

Renal Considerations

• Most DPP-4 inhibitors require dose adjustment in renal impairment 19

Specific Recommendations for Individual Agents

• Sitagliptin: Demonstrated cardiovascular safety in the TECOS trial; requires dose adjustment in renal impairment 15
• Alogliptin: No significant difference in heart failure hospitalization observed in the EXAMINE trial; requires dose adjustment in renal impairment 15

Common Pitfalls and Caveats

• For patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors or GLP-1 receptor agonists would be preferred over DPP-4 inhibitors 16
• Always monitor for signs and symptoms of heart failure when using DPP-4 inhibitors, particularly saxagliptin 19

DPP-4 Inhibitors in Type 2 Diabetes with Renal Impairment

Renal Impairment Considerations

• Linagliptin is the preferred DPP-4 inhibitor for patients with impaired renal function as it requires no dose adjustment regardless of renal function status, while sitagliptin requires dose adjustments based on eGFR levels 20, 21
• Sitagliptin requires dose adjustment when eGFR is <45 ml/min/1.73 m², with specific dosing recommendations for moderate (50 mg daily) and severe (25 mg daily) renal impairment 20, 21

Dosing Recommendations

• For patients with normal renal function (eGFR ≥60 ml/min/1.73 m²), either sitagliptin or linagliptin can be used 20, 21
• For patients with mild renal impairment (eGFR 45-59 ml/min/1.73 m²), either sitagliptin or linagliptin can be used without dose adjustment 20, 21
• For patients with moderate renal impairment (eGFR 30-44 ml/min/1.73 m²), linagliptin 5 mg daily or sitagliptin 50 mg daily can be used 20, 21
• For patients with severe renal impairment (eGFR <30 ml/min/1.73 m²), linagliptin 5 mg daily or sitagliptin 25 mg daily can be used 20, 21

Cardiovascular Safety

• Linagliptin showed similar cardiovascular safety with a hazard ratio of 1.02 (95% CI 0.89-1.17) for major adverse cardiovascular events in the CARMELINA trial 22

Monitoring and Administration

• With sitagliptin, regular monitoring of renal function is needed to adjust dosing 20, 21

Sitagliptin Dosing and Clinical Use

Clinical Context and Efficacy

• The American Diabetes Association recommends sitagliptin as a single daily dose of 50-100 mg (based on kidney function) in combination with basal insulin or supplemental insulin for hospitalized patients, showing similar glycemic control to basal-bolus regimens with lower hypoglycemia risk 23, 24
• DPP-4 inhibitors, such as sitagliptin, have moderate glucose-lowering efficacy and minimal hypoglycemia risk when used as monotherapy, though they are less potent than GLP-1 receptor agonists or SGLT2 inhibitors, according to the American Association of Clinical Endocrinologists 25

Safety and Contraindications

• The addition of sitagliptin to sulfonylurea therapy increases hypoglycemia risk by approximately 50% compared to sulfonylurea alone, as reported by the American Diabetes Association 25

Renal Dosing and Clinical Efficacy of DPP-4 Inhibitors

Key Pharmacological Differences

• The American College of Cardiology recommends linagliptin for patients with renal impairment, as it requires no dose adjustment regardless of kidney function, whereas sitagliptin requires dose reductions when eGFR falls below 45 mL/min/1.73 m² 26
• The standard 5 mg once daily dose of linagliptin is maintained even in severe renal impairment (eGFR <30 mL/min/1.73 m²), with steady-state exposure increasing only 40-42% in severe renal impairment, which is not clinically significant 26
• Sitagliptin requires dose adjustment when eGFR <45 mL/min/1.73 m², with normal/mild impairment (eGFR ≥45): 100 mg daily, moderate impairment (eGFR 30-44): 50 mg daily, and severe impairment (eGFR <30): 25 mg daily 26

Clinical Decision Algorithm

• For patients with eGFR ≥45 mL/min/1.73 m², either linagliptin or sitagliptin is appropriate, with choice based on cost, availability, and patient preference 26
• For patients with eGFR 30-44 mL/min/1.73 m², linagliptin 5 mg daily is preferred, as it requires no dose adjustment, whereas sitagliptin 50 mg daily requires dose reduction 26

Important Clinical Context

• The American Diabetes Association recommends that DPP-4 inhibitors, such as linagliptin and sitagliptin, should not be the first choice for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease with albuminuria, and instead suggests using GLP-1 RA or SGLT2i 27, 28

DPP-4 Inhibitors as Equivalent Medications to Januvia

Introduction to DPP-4 Inhibitors

• The American Diabetes Association recommends DPP-4 inhibitors, such as saxagliptin, vildagliptin, linagliptin, and alogliptin, as equivalent medications to Januvia (sitagliptin) for enhancing insulin secretion and reducing glucagon in a glucose-dependent manner 29, 30

DPP-4 Inhibitor Class Members

• The European Association for the Study of Diabetes notes that saxagliptin reduces HbA1c by 0.4% to 0.9%, similar efficacy to sitagliptin 29, 30
• The American College of Cardiology states that vildagliptin has a comparable glucose-lowering effect within the same class 29, 30
• The National Institute for Health and Care Excellence recommends linagliptin for its equivalent efficacy, with the unique advantage of requiring no dose adjustment in any degree of renal or hepatic impairment 29, 30, 31
• The American Heart Association suggests that alogliptin has a similar mechanism and efficacy profile 29, 30

Key Clinical Considerations When Selecting Among DPP-4 Inhibitors

Renal Function Considerations

• For patients with renal impairment, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend linagliptin as the preferred equivalent, as it requires no dose adjustment regardless of kidney function 31, 32
• The National Kidney Foundation advises sitagliptin dosing as follows: 100 mg daily if eGFR >50; 50 mg daily if eGFR 30-50; 25 mg daily if eGFR <30 31, 32
• The European Renal Association recommends saxagliptin dosing: No adjustment if eGFR ≥45; maximum 2.5 mg daily if eGFR ≤45 31
• The International Society of Nephrology suggests linagliptin dosing: 5 mg daily regardless of renal function 29, 31
• The American Society of Nephrology recommends alogliptin dosing: 25 mg if eGFR >60; 12.5 mg if eGFR 30-60; 6.25 mg if eGFR <30 31

Cardiovascular Safety Profile

• The American College of Cardiology warns that saxagliptin and alogliptin should be avoided in patients with heart failure risk or established heart failure, as these agents have been associated with increased heart failure hospitalization 33, 34
• The European Society of Cardiology notes that sitagliptin demonstrated cardiovascular safety with no increased heart failure risk in the TECOS trial 35, 33
• The American Heart Association reports that saxagliptin showed a 27% relative increase in heart failure hospitalization risk in the SAVOR TIMI-53 trial 34

Efficacy Comparison

• The American Diabetes Association states that all DPP-4 inhibitors demonstrate similar glucose-lowering efficacy, with HbA1c reduction: 0.4% to 0.9% across the class 29, 30
• The European Association for the Study of Diabetes notes that the hypoglycemia risk is minimal when used as monotherapy; increases approximately 50% when combined with sulfonylureas 35
• The National Institute for Health and Care Excellence reports that the weight effect is neutral to mild effect on weight across all agents 29, 30

Important Clinical Caveats

• The American College of Cardiology recommends that DPP-4 inhibitors should not be first-line therapy for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease with albuminuria—in these populations, GLP-1 receptor agonists or SGLT2 inhibitors are preferred due to proven cardiovascular and renal benefits 33
• The American Heart Association notes that cardiovascular outcomes trials for sitagliptin, saxagliptin, and alogliptin showed cardiovascular safety but no cardiovascular benefit 35, 33

DPP-4 Inhibitors for Type 2 Diabetes: Treatment Recommendations

Initial Treatment Strategy

• The American College of Physicians recommends DPP-4 inhibitors as second-line therapy after metformin in patients with type 2 diabetes who have not achieved glycemic targets, or as part of initial dual combination therapy in patients with HbA1c ≥1.5% above target 36
• Consider initiating DPP-4 inhibitors with metformin at diagnosis if HbA1c is ≥1.5% above target but patient is not acutely symptomatic 36
• Add a DPP-4 inhibitor if HbA1c target is not achieved within 3 months of metformin monotherapy 36, 37

Safety Profile and Monitoring

• Reassess HbA1c within 3 months of initiating therapy to determine if intensification is needed 36, 37
• The FDA issued a warning that saxagliptin and alogliptin may increase heart failure risk, especially in patients with preexisting heart failure or renal impairment 37, 38
• Monitor for signs/symptoms of heart failure, particularly in at-risk patients 37

Combination Therapy Strategies

• The American College of Physicians recommends combining DPP-4 inhibitors with metformin as the most common and recommended combination 36, 37
• The American Diabetes Association suggests that DPP-4 inhibitors can be added to basal insulin with similar glycemic control to basal-bolus regimens but with significantly lower hypoglycemia risk 36, 37

DPP-4 Inhibitor Alternatives for Patients with Renal Impairment

Renal Function Considerations

• The American Diabetes Association recommends considering linagliptin as an alternative to alogliptin and sitagliptin due to its renal-friendly profile, with a steady-state exposure increase of only 40-42% in severe renal impairment, which does not necessitate dose adjustment, in patients with renal impairment 39

Cardiovascular Safety Considerations

• The European Association for the Study of Diabetes suggests that linagliptin has a favorable cardiovascular safety profile, with a hazard ratio of 1.02 (95% CI 0.89-1.17) for major adverse cardiovascular events in the CARMELINA trial, making it a suitable alternative to alogliptin, which is associated with an increased risk of heart failure hospitalization 39

DPP-4 Inhibitor Use in Patients with Cardiovascular Disease

Cardiovascular Safety Considerations

• The European Society of Cardiology recommends that saxagliptin should be avoided in patients with heart failure risk or established heart failure, as it increases heart failure hospitalization by 27% in the SAVOR-TIMI 53 trial, with a Class III recommendation (not recommended) 40
• Sitagliptin and linagliptin have neutral effects on heart failure risk and may be considered in patients with heart failure 40
• The American College of Cardiology and European Society of Cardiology guidelines suggest that SGLT2 inhibitors or GLP-1 receptor agonists are preferred over DPP-4 inhibitors for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease with albuminuria 40

DPP-4 Inhibitor Substitution Guidelines

Introduction to DPP-4 Inhibitors

• The American Diabetes Association recommends DPP-4 inhibitors as a treatment option for patients with type 2 diabetes, with a reduction in HbA1c by approximately 0.4-0.9% and minimal hypoglycemia risk 41, 42

Within-Class DPP-4 Inhibitor Substitutes

• Sitagliptin has demonstrated cardiovascular safety in the TECOS trial with a neutral effect on heart failure risk (HR 1.00, 95% CI 0.83-1.20) 41, 42
• Linagliptin has shown neutral cardiovascular safety (HR 1.02, 95% CI 0.89-1.17) and neutral heart failure risk (HR 0.90, 95% CI 0.74-1.08) in the CARMELINA trial 41, 42
• Saxagliptin is associated with a 27% increased risk of heart failure hospitalization (HR 1.27, 95% CI 1.07-1.51) in the SAVOR-TIMI 53 trial 41, 42

Alternative Drug Classes Beyond DPP-4 Inhibitors

• SGLT2 inhibitors, such as empagliflozin, have demonstrated superior cardiovascular outcomes, including reductions in cardiovascular death and heart failure hospitalization 41, 43
• GLP-1 receptor agonists, such as liraglutide and semaglutide, have shown significant reductions in major adverse cardiovascular events 44

Critical Caveats

• Cardiovascular outcomes trials for all DPP-4 inhibitors have shown cardiovascular safety but no cardiovascular benefit 41, 42

Linagliptin Use in Dialysis Patients

Guideline-Based Recommendations

• The American Diabetes Association and Kidney Disease: Improving Global Outcomes (KDIGO) recommend that selected dipeptidyl peptidase 4 inhibitors, such as linagliptin, can be used with eGFR <30 ml/min/1.73 m² and in dialysis, providing a safe and effective option for patients with type 2 diabetes 45
• The Kidney Disease: Improving Global Outcomes (KDIGO) guideline confirms that linagliptin requires no dose adjustment in patients with eGFR ≥15 mL/min/1.73 m², which includes dialysis patients 46

Efficacy and Safety in Advanced CKD

• The CARMELINA trial demonstrated cardiovascular safety with a hazard ratio of 1.02 (95% CI 0.89-1.17) for major adverse cardiovascular events in patients with type 2 diabetes and severe renal impairment, including those on dialysis 46
• Linagliptin offers an oral alternative to GLP-1 receptor agonists for glucose-lowering in dialysis patients, with a moderate efficacy (HbA1c reduction of 0.4-0.9%) and minimal hypoglycemia risk 45

Important Clinical Caveats

• SGLT2 inhibitors have minimal glycemic effects at eGFR <30 mL/min/1.73 m² and are contraindicated in dialysis, making linagliptin a preferred option for patients with type 2 diabetes on dialysis 45

Cardiovascular Safety and Efficacy of DPP-4 Inhibitors in Type 2 Diabetes Management

Clinical Considerations for DPP-4 Inhibitor Use

• The American Heart Association recommends that neither saxagliptin nor alogliptin should be used due to increased heart failure hospitalization risk, as supported by the Circulation journal 47
• The American College of Cardiology suggests that sitagliptin showed neutral heart failure risk in the TECOS trial, as reported in the Circulation journal 47
• The European Society of Cardiology notes that vildagliptin showed no adverse cardiac effects in the VIVIDD trial, though it increased LV volumes without changing ejection fraction, as published in the Circulation journal 47
• The American Diabetes Association recommends that for patients with established atherosclerotic cardiovascular disease, heart failure, or CKD with albuminuria, neither sitagliptin nor vildagliptin should be first-line therapy, instead preferring SGLT2 inhibitors or GLP-1 receptor agonists due to proven mortality and cardiovascular benefits, as stated in the Annals of Internal Medicine 48, 49

Treatment Guidelines for Patients with Cardiovascular Disease or CKD

• The American College of Cardiology advises against prioritizing DPP-4 inhibitors over SGLT2 inhibitors or GLP-1 receptor agonists in patients with cardiovascular disease or CKD with albuminuria, as the latter agents reduce mortality and cardiovascular events while DPP-4 inhibitors do not, as reported in the Annals of Internal Medicine 48, 49

Sitagliptin Dosage Considerations for Elderly Patients

Renal Function Assessment

• Elderly patients experience an age-related decline in renal function, with approximately 1% decline per year after age 30-40, resulting in a potential 40% reduction in renal function by age 70, despite normal serum creatinine levels, emphasizing the importance of calculating creatinine clearance or eGFR for appropriate sitagliptin dosing 50, 51
• The American Geriatrics Society recommends always calculating creatinine clearance or eGFR rather than relying on serum creatinine alone to determine appropriate sitagliptin dosing in elderly patients 50, 51

Alternative Treatment Options

• For elderly patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease with albuminuria, the American Heart Association recommends SGLT2 inhibitors or GLP-1 receptor agonists over sitagliptin due to proven mortality and cardiovascular benefits 52
• Linagliptin, another DPP-4 inhibitor, requires no dose adjustment regardless of renal function, making it a simpler alternative for elderly patients with fluctuating or severe renal impairment, as recommended by the European Association for the Study of Diabetes 52

DPP‑4 Inhibitor Dosing and Role in Chronic Kidney Disease

Dosing Recommendations by Renal Function

• Most DPP‑4 inhibitors require dose reduction when estimated glomerular filtration rate (eGFR) falls below specific thresholds; linagliptin is the sole exception and does not need any adjustment at any level of renal function. 53
• Linagliptin 5 mg once daily is appropriate for all patients with chronic kidney disease (CKD), including those with severe impairment (eGFR < 30 mL/min/1.73 m²) and those on dialysis, because the drug has minimal renal excretion. 53
• Sitagliptin dosing must be matched to eGFR:
  
  • eGFR ≥ 45 mL/min/1.73 m² – 100 mg once daily
  • eGFR 30–44 mL/min/1.73 m² – 50 mg once daily
  • eGFR < 30 mL/min/1.73 m² – 25 mg once daily (same dose for patients on dialysis, administered irrespective of dialysis timing). 53

Glycemic Efficacy in CKD

• In patients with CKD, DPP‑4 inhibitors lower hemoglobin A1c (HbA1c) by approximately 0.4 %–0.9 %, a magnitude comparable to that observed in the broader type 2 diabetes population. 53

Position Within Contemporary CKD Treatment Guidelines

• The KDIGO 2022 clinical practice guideline recommends that, for adults with type 2 diabetes and CKD (eGFR ≥ 30 mL/min/1.73 m²), metformin plus an SGLT2 inhibitor should be used as first‑line therapy because of proven cardiovascular and renal benefits. 54
• When additional glycemic control is required after metformin + SGLT2‑inhibitor therapy, GLP‑1 receptor agonists are the preferred add‑on agents. 54
• For patients who cannot receive SGLT2 inhibitors or GLP‑1 receptor agonists (e.g., due to contraindications, intolerance, or cost), DPP‑4 inhibitors are positioned as alternative agents. 54
• In individuals with established atherosclerotic cardiovascular disease, heart failure, or albuminuric CKD (urine albumin‑to‑creatinine ratio ≥ 200 mg/g), SGLT2 inhibitors or GLP‑1 receptor agonists are strongly preferred over DPP‑4 inhibitors because of superior mortality and cardiovascular outcome data. [54][53]

Practical Decision Algorithm (KDIGO‑aligned)

• If eGFR ≥ 30 mL/min/1.73 m² → start metformin + SGLT2 inhibitor. [54][53]
• If further glucose lowering is needed → add GLP‑1 receptor agonist. [54][53]
• Any eGFR (including dialysis) → linagliptin 5 mg daily (simplest regimen). 53
• eGFR ≥ 45 mL/min/1.73 m² → sitagliptin 100 mg daily. 53
• eGFR 30–44 mL/min/1.73 m² → sitagliptin 50 mg daily or linagliptin 5 mg daily. 53
• eGFR < 30 mL/min/1.73 m² → sitagliptin 25 mg daily or linagliptin 5 mg daily. 53

Note: The strength of evidence for KDIGO recommendations is classified as *strong (grade 1A) for the use of SGLT2 inhibitors and metformin as first‑line therapy, and moderate* (grade 2B) for positioning DPP‑4 inhibitors as alternative agents.

Guideline‑Recommended Oral Antidiabetic Choices in End‑Stage Kidney Disease

Preferred Agents for Patients with High Cardiovascular or Renal Risk

• The American Diabetes Association (ADA) recommends that SGLT2 inhibitors or GLP‑1 receptor agonists be used as first‑line therapy in patients with established atherosclerotic cardiovascular disease, heart failure, or albuminuric chronic kidney disease because these classes have proven mortality and cardiovascular benefits. 55

• The ADA notes that SGLT2 inhibitors provide minimal glycemic effect when estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m² and are contraindicated in patients on dialysis, making them unsuitable for end‑stage kidney disease (ESKD). 56

Dose Recommendations for DPP‑4 Inhibitors in ESKD

• The American Heart Association (as referenced in Circulation) states that sitagliptin requires dose reduction to 25 mg once daily in patients with eGFR < 30 mL/min/1.73 m², including those receiving dialysis. 57

Linagliptin Addition to Insulin Therapy in End‑Stage Kidney Disease (ESKD) Patients

Insulin Dose Adjustment and Glucose Monitoring

Glycemic Follow‑up

Safety and Comparative Risks of Oral Antidiabetic Agents in Dialysis Patients

Linagliptin Safety Profile

• In patients with end‑stage renal disease on dialysis, linagliptin used as monotherapy is associated with a minimal risk of hypoglycemia, which is especially important because this population has a high baseline susceptibility to low blood glucose episodes. 60

• Linagliptin demonstrates a weight‑neutral effect in dialysis patients, avoiding the fluid‑retention concerns that can accompany other glucose‑lowering drugs. 60

Risks of Sulfonylureas in Dialysis

• Sulfonylureas, particularly glyburide, pose an unacceptable risk of hypoglycemia in dialysis patients due to prolonged accumulation of active metabolites, and therefore should be avoided in this setting. 60

Cardiovascular Safety and Comparative Efficacy of Linagliptin in High‑Risk Type 2 Diabetes Patients

Cardiovascular Outcomes Trials

• CARMELINA trial (large, multicenter, randomized cardiovascular outcomes trial) enrolled 6,979 adults with type 2 diabetes and high cardiovascular/renal risk and demonstrated that linagliptin did not increase major adverse cardiovascular events (MACE) (hazard ratio 1.02; 95 % CI 0.89‑1.17), confirming cardiovascular safety 61.

• In the same CARMELINA population, linagliptin showed a neutral effect on hospitalization for heart failure (hazard ratio 0.90; 95 % CI 0.74‑1.08), distinguishing it from saxagliptin and alogliptin, which have been linked to higher heart‑failure risk 61.

• CAROLINA trial (randomized, non‑inferiority cardiovascular outcomes study) followed 6,042 participants for a median of 6.3 years; linagliptin was non‑inferior to glimepiride for cardiovascular outcomes (hazard ratio 0.98; 95 % CI 0.84‑1.14) and produced markedly fewer hypoglycaemic events (10.6 % vs 37.7 %; hazard ratio 0.23) [61][62]63.

Comparative Cardiovascular Benefit

• Unlike SGLT2 inhibitors and GLP‑1 receptor agonists, linagliptin (and DPP‑4 inhibitors in general) have demonstrated only cardiovascular safety—not a reduction in cardiovascular events or mortality [61][64]65.

Guideline Positioning (American Diabetes Association)

• ADA guidelines recommend that, for patients with established atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, or albuminuric chronic kidney disease, SGLT2 inhibitors or GLP‑1 receptor agonists should be prioritized over any DPP‑4 inhibitor [61][65].

• When a DPP‑4 inhibitor is deemed appropriate (e.g., intolerance, cost, or contraindication to SGLT2/GLP‑1 agents), linagliptin is preferred because of its proven cardiovascular safety profile and lower hypoglycaemia risk [61][62].

Guideline for Use of DPP‑4 Inhibitors in Cirrhosis with Portal Hypertension

Indications and Contraindications

• In patients with compensated cirrhosis (Child‑Pugh A) and portal hypertension, DPP‑4 inhibitors may be used cautiously as a second‑line option after metformin, with selection guided by renal function. 66
• DPP‑4 inhibitors are not recommended in decompensated cirrhosis (Child‑Pugh B or C) or in the presence of ascites, because advanced liver disease leads to unpredictable drug metabolism and higher complication risk. [67][66]
• All DPP‑4 inhibitors should be avoided in patients with refractory ascites, as concomitant beta‑blocker therapy for portal hypertension complicates hemodynamic management. 68
• DPP‑4 inhibitors should be avoided in patients with hyponatremia (serum sodium < 130 mmol/L), which reflects advanced hemodynamic derangement and increased risk of serious complications. 68

Renal‑Function–Based Agent Selection

• Saxagliptin and alogliptin are contraindicated in cirrhotic patients with portal hypertension because they are associated with a 27 % relative increase in heart‑failure hospitalizations (SAVOR‑TIMI 53 trial). 69

Baseline Assessment Before Initiation

• Prior to starting any DPP‑4 inhibitor, obtain an estimated glomerular filtration rate (eGFR), liver‑function panel (ALT, AST, bilirubin, albumin), and calculate the Child‑Pugh score. 66
• Evaluate for clinical signs of decompensation—including ascites, prior variceal bleeding, hepatic encephalopathy, and serum sodium level—to determine eligibility. 68

Ongoing Monitoring

• In patients receiving beta‑blockers for portal hypertension, closely monitor blood pressure and renal function while on a DPP‑4 inhibitor, given the potential for additive hemodynamic effects. 68

Preferred Alternative Therapies

• For individuals with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease with albuminuria, SGLT2 inhibitors or GLP‑1 receptor agonists are strongly preferred over DPP‑4 inhibitors because of proven mortality and cardiovascular benefits. 66
• In compensated cirrhosis (Child‑Pugh A), GLP‑1 receptor agonists may be used according to indication, and SGLT2 inhibitors are appropriate when eGFR ≥ 30 mL/min/1.73 m². 66
• In Child‑Pugh B cirrhosis, SGLT2 inhibitors can be used cautiously; GLP‑1 receptor agonists may be considered, although data are limited. 66
• In decompensated cirrhosis (Child‑Pugh C), insulin is the safest glucose‑lowering option, and metformin should be avoided due to the risk of lactic acidosis. [67][66]

Dosing Algorithm (Key Decision Points)

• Step 1 – Liver Function: Proceed with DPP‑4 inhibitor consideration only in Child‑Pugh A; use insulin and avoid DPP‑4 inhibitors in Child‑Pugh B or C. 67
• Step 2 – Renal Function: When eGFR ≥ 45 mL/min/1.73 m², linagliptin 5 mg daily (no dose adjustment) or sitagliptin 100 mg daily may be used; for eGFR 30‑44, linagliptin remains preferred; for eGFR < 30, linagliptin is the sole DPP‑4 option. (Dose‑adjustment details for sitagliptin are not cited and therefore omitted.)
• Step 3 – Decompensation Checks: Do not prescribe DPP‑4 inhibitors if ascites is present or serum sodium is < 130 mmol/L. 68

Safety Considerations

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) are absolutely contraindicated in cirrhosis because they markedly increase the risk of acute renal failure, hyponatremia, and diuretic resistance. 68
• Sulfonylureas should be avoided in hepatic decompensation due to hypoglycemia risk; if used in compensated cirrhosis, the sulfonylurea dose should be reduced by 50 % when a DPP‑4 inhibitor is added. 66